Ignite Creation Date:
2024-05-05 @ 12:06 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00240006
Status:
COMPLETED
Last Update Posted:
2011-04-11
First Post:
2005-10-13
Brief Title:
A Study Comparing Shared Solutions Plus MS Center Support Versus Shared Solutions Alone
Sponsor:
Teva Neuroscience Inc
Organization:
Teva Branded Pharmaceutical Products RD Inc
Study Overview
Official Title:
An Open Label Prospective Parallel Cohort Study Comparing A 90-day Copaxone Adherence Enhancement Program Among Persons With Multiple Sclerosis Who Participate in Shared Solutions Alone or in Partnership With Their MS Center
Status:
COMPLETED
Status Verified Date:
2011-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To compare the effectiveness of a 90-day Copaxone adherence enhancement program for a sample of MS patients who are at high risk of nonadherence and receive support from Shared Solutions and their MS Center versus those who receive support only from Shared Solutions
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None